First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

doi:10.1016/j.lungcan.2010.07.008

Article

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2011

Salazar Fernanda, Molina Miguel Angel, Sanchez-Ronco Maria, Moran Teresa, Ramirez Jose Luis, Sanchez Jose Miguel, Stahel Rolf, Garrido Pilar, Cobo Manuel, Isla Dolores, Bertran-Alamillo Jordi, Massuti Bartomeu, Cardenal Felipe, Manegold Christian, Lianes Pilar, Trigo Jose Manuel, Sanchez Jose Javier, Taron Miquel, Rosell Rafael

Abstract excerpt

The potential differential effect of first-line treatment and molecular mechanisms on survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) has not been fully investigated. In particular, CHFR is frequently methylated in NSCLC and may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Abstract excerpt

Topics

Related research